Penelope Przekop: Bringing the science of quality management to the pharma sector

September 12, 2021
By Penelope Przekop
Leadership
Quality
Corporate

In an interview with PerceptivX, Penelope shares exclusive insight on her background and why it’s high time to revolutionize regulatory compliance strategy in the pharmaceutical industry. She also spoke about the importance of leading authentically, overcoming fears to achieve goals and things she’d like most to change about the world.

About the Author

Penelope Przekop, CEO

MSQA, RQAP-GCP

Penelope Przekop is a is a biopharmaceutical quality assurance and corporate compliance executive consultant with global R&D and commercial PV expertise. During the early 2000s, she developed and oversaw the first global PV quality and compliance departments established for Wyeth as well as Johson & Johnson. Her work includes qualification and oversight of numerous PV vendors covering all aspects of clinical safety and post-marketed PV. Penelope has facilitated numerous PV regulatory inspections. She frequently leads and conducts PV mock inspections and provides in-depth PV training.

Related Content

Read more from PDC’s teams of experts.

10 Key Ingredients For Small Pharma GCP Quality Systems

Small to midsize pharmaceutical or biotech companies (small pharma) are enjoying the best of times. Many have exciting products with fantastic preclinical and/or clinical results, great platforms for long-term company growth and licensing possibilities, outstanding medical and technical expertise, and support from intellectual/academic experts. However, from a quality systems perspective, it could be the worst of times. Many have weak quality systems, are not following global regulatory authority regulations and/or guidance, or lack the level of documentation required to reconstruct every aspect of clinical trials.

Learn more
10 Key Ingredients For Small Pharma GCP Quality Systems

Small to midsize pharmaceutical or biotech companies (small pharma) are enjoying the best of times. Many have exciting products with fantastic preclinical and/or clinical results, great platforms for long-term company growth and licensing possibilities, outstanding medical and technical expertise, and support from intellectual/academic experts. However, from a quality systems perspective, it could be the worst of times. Many have weak quality systems, are not following global regulatory authority regulations and/or guidance, or lack the level of documentation required to reconstruct every aspect of clinical trials.

Learn more
The FDA Speaks Up For Quality Management: Must They Beg?

On Jan. 31, 2024, the FDA, in collaboration with the Duke-Margolis Institute for Health Policy, convened a public workshop, Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches.

Learn more
The FDA Speaks Up For Quality Management: Must They Beg?

On Jan. 31, 2024, the FDA, in collaboration with the Duke-Margolis Institute for Health Policy, convened a public workshop, Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more
Your New 6-Step Approach For CRO Selection In 2022

Unfortunately, whether you've chosen the right clinical research organization (CRO) isn't always obvious until contracts are signed and patients are enrolled. In 2022, basic industry standard steps are being skipped left and right. Here are 6 win-win suggestions to incorporate into your vendor selection strategy/

Learn more
Your New 6-Step Approach For CRO Selection In 2022

Unfortunately, whether you've chosen the right clinical research organization (CRO) isn't always obvious until contracts are signed and patients are enrolled. In 2022, basic industry standard steps are being skipped left and right. Here are 6 win-win suggestions to incorporate into your vendor selection strategy/

Learn more

How can we help you?

Reach out to schedule a consultation.

Contact PDC